Google
Trusted Resources: News & Events
Latest announcements and gatherings
NIH Launches new Collaboration to Develop Gene-Based Cures for Sickle Cell Disease and HIV on Global Scale
The National Institutes of Health plans to invest at least $100 million over the next four years toward an audacious goal: develop affordable, gene-based cures for sickle cell disease (SCD) and HIV. The Bill & Melinda Gates Foundation will also invest $100 million toward this goal. The intention is for these cures to be made globally available, including in low-resource settings.
This initiative follows a bold announcement made earlier this year by President Donald J. Trump during the State of the Union Address to end the HIV epidemic in the United States in the next 10 years. Ending the HIV Epidemic: A Plan for America(link is external) aims to leverage the powerful data and tools now available to reduce new HIV diagnoses in the United States by 75% in five years and by 90% by 2030. The Trump Administration has also elevated the attention paid to sickle cell disease, identifying it as an intractable health challenge with the potential for dramatic advances in the coming years.
+myBinderRelated Content
-
FDA Clears Graphite Bio to Begin Trial for Gene Therapy in Sickle Cell DiseaseIn response to Graphite Bio’s investig...
-
Today’s Faces of Sickle Cell Disease: Rodrick MurrayRodrick Murray was 3 months old when he ...
-
In A 1st, Doctors In U.S. Use CRISPR Tool To Treat Patient With Genetic DisorderFor the first time, doctors in the U.S. ...
-
At 16, She’s a Pioneer in the Fight to Cure Sickle Cell DiseaseHelen Obando, a shy slip of a girl, lay ...
-
SCDAA News Advisory: Partial Hold on Gene Therapy TrialOn December 20, the FDA placed a partial...
-
MARAC Advisory Statement: Gene Therapy & Bone Marrow TherapiesPlease note: A previous version of this ...
-
Podcast: How New Gene Therapies for SCD May Impact Women’s FertilityAs we closed 2023, the Food and Drug Ad...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.